［1］STUELTEN CH,PARENT CA,MONTELL DJ.Cell motility in cancer invasion and metastasis:insights from simple model organisms［J］.Nat Rev Cancer,2018,18(5):296-312.
［2］CHAFFER CL,WEINBERG RA.A perspective on cancer cell metastasis［J］.Science,2011,331(6024):1559-1564.
［3］SAXENA K,SRIKRISHNAN S,CELIA-TERRASSA T,et al.OVOL1/2:Drivers of epithelial differentiation in development,disease,and reprogramming［J］.Cells Tissues Organs,2022,211(2):183-192.
［4］LEE B,VILLARREAL-PONCE A,FALLAHI M,et al.Transcriptional mechanisms link epithelial plasticity to adhesion and differentiation of epidermal progenitor cells［J］.Dev Cell,2014,29(1):47-58.
［5］WATANABE K,VILLARREAL-PONCE A,SUN P,et al.Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor［J］.Dev Cell,2014,29(1):59-74.
［6］OLIVER B,PERRIMON N,MAHOWALD AP.The ovo locus is required for sex-specific germ line maintenance in Drosophila［J］.Genes Dev,1987,1(9):913-923.
［7］TSUJI G,ITO T,CHIBA T,et al.The role of the OVOL1-OVOL2 axis in normal and diseased human skin［J］.J Dermatol Sci,2018,90(3):227-231.
［8］KUMAR A,BHANDARI A,SINHA R,et al.Molecular phylogeny of OVOL genes illustrates a conserved C2H2 zinc finger domain coupled by hypervariable unstructured regions［J］.PLoS One,2012,7(6):e39399.
［9］NAIR M,BILANCHONE V,ORTT K,et al.Ovol1 represses its own transcription by competing with transcription activator c-Myb and by recruiting histone deacetylase activity［J］.Nucleic Acids Res,2007,35(5):1687-1697.
［10］YE GD,SUN GB,JIAO P,et al.OVOL2,an inhibitor of WNT signaling,reduces invasive activities of human and mouse cancer cells and is down-regulated in human colorectal tumors［J］.Gastroenterology,2016,150(3):659-671,e616.
［11］ZHANG X,LUO F,LUO S,et al.Transcriptional repression of aerobic glycolysis by OVOL2 in breast cancer［J］.Adv Sci(Weinh),2022,9(27):e2200705.
［12］DAI X,SCHONBAUM C,DEGENSTEIN L,et al.The ovo gene required for cuticle formation and oogenesis in flies is involved in hair formation and spermatogenesis in mice［J］.Genes Dev,1998,12(21):3452-3463.
［13］LI S,YANG J.Ovol proteins:guardians against EMT during epithelial differentiation［J］.Dev Cell,2014,29(1):1-2.
［14］LI B,DAI Q,LI L,et al.Ovol2,a mammalian homolog of Drosophila ovo:gene structure,chromosomal mapping,and aberrant expression in blind-sterile mice［J］.Genomics,2002,80(3):319-325.
［15］BERGERS G,FENDT SM.The metabolism of cancer cells during metastasis［J］.Nat Rev Cancer,2021,21(3):162-180.
［16］LU W,KANG Y.Epithelial-mesenchymal plasticity in cancer progression and metastasis［J］.Dev Cell,2019,49(3):361-374.
［17］ROCA H,HERNANDEZ J,WEIDNER S,et al.Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer［J］.PLoS One,2013,8(10):e76773.
［18］QI XK,HAN HQ,ZHANG HJ,et al.OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma［J］.Theranostics,2018,8(8):2202-2216.
［19］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［20］LIANG Y,ZHANG H,SONG X,et al.Metastatic heterogeneity of breast cancer:Molecular mechanism and potential therapeutic targets［J］.Semin Cancer Biol,2020,60:14-27.
［21］WU RS,LIN J,XING YM,et al.OVOL2 inhibits macrophage M2 polarization by regulating IL-10 transcription,and thus inhibits the tumor metastasis by modulating the tumor microenvironment［J］.Immunol Lett,2022,242:17-26.
［22］DURUISSEAUX M,ESTELLER M.Lung cancer epigenetics:From knowledge to applications［J］.Semin Cancer Biol,2018,51:116-128.
［23］SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2018［J］.CA Cancer J Clin,2018,68(1):7-30.
［24］HERBST RS,MORGENSZTERN D,BOSHOFF C.The biology and management of non-small cell lung cancer［J］.Nature,2018,553(7689):446-454.
［25］WANG ZH,LI Z,HU M,et al.Ovol2 gene inhibits the epithelial-to-mesenchymal transition in lung adenocarcinoma by transcriptionally repressing Twist1［J］.Gene,2017,600:1-8.
［26］BILLER LH,SCHRAG D.Diagnosis and treatment of metastatic colorectal cancer:A review［J］.JAMA,2021,325(7):669-685.
［27］ALLGAYER H,LEUPOLD JH,PATIL N.Defining the "Metastasome":Perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences［J］.Semin Cancer Biol,2020,60:1-13.
［28］SCHLICK CJR,MERKOW RP,BENTREM DJ.Nonresectional regional therapies for metastatic colorectal cancer to the liver［J］.J Surg Oncol,2019,119(5):636-641.
［29］FAROOQI AA,DE LA ROCHE M,DJAMGOZ MBA,et al.Overview of the oncogenic signaling pathways in colorectal cancer:Mechanistic insights［J］.Semin Cancer Biol,2019,58:65-79.
［30］PRETZSCH E,BOSCH F,NEUMANN J,et al.Mechanisms of metastasis in colorectal cancer and metastatic organotropism:Hematogenous versus peritoneal spread［J］.J Oncol,2019,2019:7407190.
［31］XIA L,GAO J,MA K,et al.OVOL2 attenuates the expression of MAP3K8 to suppress epithelial mesenchymal transition in colorectal cancer［J］.Pathol Res Pract,2021,224:153493.
［32］CHAKRABORTY E,SARKAR D.Emerging therapies for hepatocellular carcinoma(HCC)［J］.Cancers(Basel),2022,14(11):2798.
［33］GE Y,MU W,BA Q,et al.Hepatocellular carcinoma-derived exosomes in organotropic metastasis,recurrence and early diagnosis application［J］.Cancer Lett,2020,477:41-48.
［34］FU H,QI L,CHEN L,et al.Expression of Ovol2 is related to epithelial characteristics and shows a favorable clinical outcome in hepatocellular carcinoma［J］.Onco Targets Ther,2016,9:5963-5973.
［35］TSANG CM,LUI VWY,BRUCE JP,et al.Translational genomics of nasopharyngeal cancer［J］.Semin Cancer Biol,2020,61:84-100.
［36］SIAK PY,KHOO AS,LEONG CO,et al.Current status and future perspectives about molecular biomarkers of nasopharyngeal carcinoma［J］.Cancers(Basel),2021,13(14):3490.
［37］JIANG X,FENG L,DAI B,et al.Identification of key genes involved in nasopharyngeal carcinoma［J］.Braz J Otorhinolaryngol,2017,83(6):670-676.
［38］STRASHILOV S,YORDANOV A.Aetiology and pathogenesis of cutaneous melanoma:Current concepts and advances［J］.Int J Mol Sci,2021,22(12):6395.
［39］RUOCCO MR,AVAGLIANO A,GRANATO G,et al.Metabolic flexibility in melanoma:A potential therapeutic target［J］.Semin Cancer Biol,2019,59:187-207.
［40］GARBE C,AMARAL T,PERIS K,et al.European consensus-based interdisciplinary guideline for melanoma.Part 1:Diagnostics:Update 2022［J］.Eur J Cancer,2022,170:236-255.
［41］WOUTERS J,VIZOSO M,MARTINEZ-CARDUS A,et al.Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma［J］.BMC Med,2017,15(1):101.
［42］CHANG MS,AZIN M,DEMEHRI S.Cutaneous squamous cell carcinoma:The frontier of cancer immunoprevention［J］.Annu Rev Pathol,2022,17:101-119.
［43］KALLINI JR,HAMED N,KHACHEMOUNE A.Squamous cell carcinoma of the skin:epidemiology,classification,management,and novel trends［J］.Int J Dermatol,2015,54(2):130-140.
［44］CORCHADO-COBOS R,GARCIA-SANCHA N,GONZALEZ-SARMIENTO R,et al.Cutaneous squamous cell carcinoma:From biology to therapy［J］.Int J Mol Sci,2020,21(8):2956.
［45］ITO T,TSUJI G,OHNO F,et al.Potential role of the OVOL1-OVOL2 axis and c-Myc in the progression of cutaneous squamous cell carcinoma［J］.Mod Pathol,2017,30(7):919-927.
［46］BERISH RB,ALI AN,TELMER PG,et al.Translational models of prostate cancer bone metastasis［J］.Nat Rev Urol,2018,15(7):403-421.
［47］CAO M,SHI E,WANG H,et al.Personalized targeted therapeutic strategies against oral squamous cell carcinoma.An evidence-based review of literature［J］.Int J Nanomedicine,2022,17:4293-4306.
［48］CHI AC,DAY TA,NEVILLE BW.Oral cavity and oropharyngeal squamous cell carcinoma-an update［J］.CA Cancer J Clin,2015,65(5):401-421.
［49］CHOW LQM.Head and neck cancer［J］.N Engl J Med,2020,382(1):60-72.
［50］JENSEN DH,DABELSTEEN E,SPECHT L,et al.Molecular profiling of tumour budding implicates TGFbeta-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma［J］.J Pathol,2015,236(4):505-516.
［51］SURIYAMURTHY S,BAKER D,TEN DIJKE P,et al.Epigenetic reprogramming of TGF-beta signaling in breast cancer［J］.Cancers(Basel),2019,11(5):726.
［52］FAN C,WANG Q,VAN DER ZON G,et al.OVOL1 inhibits breast cancer cell invasion by enhancing the degradation of TGF-beta type I receptor［J］.Signal Transduct Target Ther,2022,7(1):126.
［53］WU RS,HONG JJ,WU JF,et al.OVOL2 antagonizes TGF-beta signaling to regulate epithelial to mesenchymal transition during mammary tumor metastasis［J］.Oncotarget,2017,8(24):39401-39416.